Rindopepimut is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Rindopepimut becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Information about NationDrugs.to
List of countries where we can ship Rindopepimut:
Latest news releases on Rindopepimut:
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.
Rindopepimut did not increase survival in patients with newly diagnosed glioblastoma. Combination approaches potentially including rindopepimut might be required to ...
Rindopepimut ®: A promising immunotherapeutic for the treatment of glioblastoma multiforme. AM Swartz, QJ Li, and JH Sampson, MD, PhD ... Rindopepimut ® is emerging ...
This trial is looking at a new treatment called rindopepimut alongside temozolomide for people with a type of brain tumour called glioblastoma.
Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma
Rindopepimut is an immunotherapeutic molecule that consists of a peptide (EGFRvIII) from a tumour-specific splice variant of the epidermal growth factor
• Vaccination against EGFRvIII (Rindopepimut, Rintega®, Celldex)
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug ...
Learn about the targeted therapeutics being developed by Celldex Therapeutics.